RETRACTION

After manuscript acceptance and publication online as an uncorrected author proof, irregularities in conflict of interest disclosures and data presentation were noted in the article entitled “Enhanced Detection and Phenotypic and Karyotypic in Situ Characterization of Circulating Tumor Cells,” which appeared online October 16, 2014, in The American Journal of Pathology (http://dx.doi.org/10.1016/j.ajpath.2014.08.023). It was determined that although author employment by Cytelligen (San Diego, CA) was disclosed, Dr. Peter P. Lin did not disclose his role as President of Cytelligen, which according to the company website “specializes in circulating rare cell including circulating tumor cell (CTC) related clinical application and scientific research.” Cytelligen was also not disclosed as being a source of reagents in Materials and Methods. Additionally, figures present in the article had been previously published in other journals. Specifically, a figure labeled as a circulating colon cancer cell was previously published in Clinica Chimica Acta (2013, 419:57-61) labeled as lung cancer CTC. Another figure showing CellSearch data was previously published in Oncotarget (2014, 5:6594-6602). Following editorial communication with the authors, corresponding author Dr. Marc Shuman requested that the manuscript be withdrawn, with concurrence of the Editors. Acceptance of the manuscript is therefore being withdrawn from The American Journal of Pathology by the American Society for Investigative Pathology. All authors have been notified of this decision.